Because of the favorable treatment outcomes for human papillomavirus (HPV)–associated oropharyngeal squamous cell cancer (OPSCC), efforts are ongoing to reduce the burden and cost of posttreatment surveillance. National Comprehensive Cancer Network (NCCN) guidelines recommend 1 imaging study (positron emission tomography/computed tomography [PET/CT] preferred) 8 to 12 weeks after completion of radiotherapy and/or chemotherapy, but additional imaging studies are commonly ordered.
1 Circulating tumor DNA (ctDNA) has shown impressive predictive value in surveillance across multiple malignant neoplasms, with positive and negative predictive values of 94% and 100%, respectively, for HPV-associated OPSCC.
2 We undertook a cross-sectional cost comparison of ctDNA utilization for posttreatment surveillance of HPV-associated OPSCC, which may offer equivalent or even improved accuracy compared with existing imaging strategies.